CoChat
Sign Up
Cited by 112Antifungal resistance and susceptibilityCOVID-19 Clinical Research StudiesCOVID-19 and healthcare impacts

The DOI matches its Crossref record; 4 of the 5 references it cites were found in a registry or an index.

Candidemia in Coronavirus Disease 2019 (COVID-19) Patients: Incidence and Characteristics in a Prospective Cohort Compared With Historical Non–COVID-19 Controls

Open access
Mastrangelo, Andrea, Germinario, Bruno Nicolò, Ferrante, Marica, Frangi, Claudia, Li Voti, Raffaele, Muccini, Camilla, Ripa, Marco, COVID-BioB Study Group, Canetti, Diana, Castiglioni, Barbara, Oltolini, Chiara, Tassan Din, Chiara, Conte, Caterina, Monti, Giacomo, Dagna, Lorenzo, Clementi, Massimo, Rovere Querini, Patrizia, Ciceri, Fabio, Tresoldi, Moreno, Cinque, Paola, Lazzarin, Adriano, Zangrillo, Alberto, Secchi, Antonio, Bosi, Emanuele, Scarpellini, Paolo, Castagna, Antonella·2021·Clinical Infectious Diseases
DOI 10.1093/cid/ciaa1594PMC PMC7665423
Open this paper in CoChat — free account

Abstract

To the Editor—We read with interest the article by White and colleagues, who provide insights on invasive fungal infections in coronavirus disease 2019 (COVID-19) patients [1]. The authors describe a significant proportion of invasive yeast infections, especially candidemia. To date, it is not clear if the incidence of candidemia in COVID-19 patients is higher than expected. Moreover, no comparison of clinical presentation and outcomes between patients with and without COVID-19 is available. To investigate these points, we compared the incidence and characteristics of candidemia in a prospective cohort of patients with severe acute respiratory syndrome coronavirus 2 infection to those of a historical cohort of non–COVID-19 controls. We included patients with candidemia (defined as 1 or more positive blood cultures for Candida spp.) hospitalized at the San Raffaele Hospital (Milan, Italy) with COVID-19 from 15 February 2020 to 30 June 2020 and patients hospitalized for any reason from 1 January 2017 to 31 December 2017 (historical non–COVID-19 cohort). An ethical committee approved data collection for both cohort studies. The Pearson χ 2 test and Mann-Whitney U test were applied, as appropriate. The incidence rate was calculated as events per 10.000 person-days of follow-up (PDFU) and compared using Poisson regression. Statistical analysis was performed with SPSS-v.20 (IBM, Chicago, IL). We identified 21 and 51 patients in the COVID-19 and historical cohorts, respectively (Table 1). The incidence rate of candidemia was significantly higher in patients with COVID-19 (10.97 [6.79–16.76] vs 1.48 [1.10–1.95] cases per 10.000 PDFU; P < .001). Characteristics of the 2 Cohorts of Patients With Candidemia Values are reported as median, interquartile range, or frequency (%). P-values <0.05 are presented in bold. Abbreviation: COVID-19, coronavirus disease 2019. aLess than 5 years of negative follow-up since the last potentially curative intervention. bAdministration of chemotherapies during the 90 days before candidemia. cAdministration of antimicrobials during the 14 days before candidemia. dAdministration of immunomodulating drugs (anakinra, tocilizumab, reparixin, mavrilimumab, sarilumab) and/or immunosuppressive drugs (cyclophosphamide, tacrolimus, mycophenolate) in the last 30 days before candidemia. eAdministration of 0.5–1 mg/kg of prednisone equivalent in the last 30 days before candidemia. fPositive Candida spp. culture from nonsterile site and/or clinical signs and symptoms compatible with skin or mucous membrane fungal infection. gAny major surgical procedure in the last 30 days. hTwo negative sets of blood cultures collected after at least 48 hours from initiation of an appropriate therapy. Characteristics of the 2 Cohorts of Patients With Candidemia Values are reported as median, interquartile range, or frequency (%). P-values <0.05 are presented in bold. Abbreviation: COVID-19, coronavirus disease 2019. aLess than 5 years of negative follow-up since the last potentially curative intervention. bAdministration of chemotherapies during the 90 days before candidemia. cAdministration of antimicrobials during the 14 days before candidemia. dAdministration of immunomodulating drugs (anakinra, tocilizumab, reparixin, mavrilimumab, sarilumab) and/or immunosuppressive drugs (cyclophosphamide, tacrolimus, mycophenolate) in the last 30 days before candidemia. eAdministration of 0.5–1 mg/kg of prednisone equivalent in the last 30 days before candidemia. fPositive Candida spp. culture from nonsterile site and/or clinical signs and symptoms compatible with skin or mucous membrane fungal infection. gAny major surgical procedure in the last 30 days. hTwo negative sets of blood cultures collected after at least 48 hours from initiation of an appropriate therapy. Candida albicans was the most frequently involved pathogen, even though non-albicans Candida spp. were detected in a considerable proportion of patients (33.3% vs 47.1%; P = .285). Infective endocarditis and endophthalmitis were rarely encountered. Candidemia clearance was obtained in most patients (71.4% vs 72.5%; P = .923), but overall mortality was high (57.1% vs 58.8%; P = .895). COVID-19 patients had a lower median Charlson comorbidity index, and no differences were detected in prior use of antibiotics, antifungal agents, parenteral nutrition, or other conditions potentially predisposing to candidemia, except for a higher proportion of patients with solid malignancies and recent chemotherapies in the historical cohort. COVID-19 patients were more likely to be in the intensive care unit (ICU; 66.7% vs 29.4%; P = .003) and to be treated with immunosuppressive agents (61.1% vs 32.7%; P = .035); the proportion of patients on glucocorticoids was not different (44.4% vs 30.6%; P = .291). When calculated for ICU patients only, the incidence rate of candidemia was still markedly higher in COVID-19 patients (81.68 [44.46–137.10] vs 14.46 [8.09–23.84] cases per 10.000

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciaa1594

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Mastrangelo, A., Germinario, B. N., Ferrante, M., Frangi, C., Li Voti, R., Muccini, C., Ripa, M., COVID-BioB Study Group, Canetti, D., Castiglioni, B., Oltolini, C., Tassan Din, C., Conte, C., Monti, G., Dagna, L., Clementi, M., Rovere Querini, P., Ciceri, F., Tresoldi, M., Cinque, P., Lazzarin, A., Zangrillo, A., Secchi, A., Bosi, E., Scarpellini, P., & Castagna, A.
Affiliations
  • School of Infectious and Tropical Diseases, Vita-Salute San Raffaele University, Milan, Italy
  • Vita-Salute San Raffaele University (IT)
  • School of Emergency Medicine, Vita-Salute San Raffaele University, Milan, Italy
Corresponding author
Ripa, Marco
ORCID
Venue
Clinical Infectious Diseases
Publisher
Oxford University Press (OUP)
Published
2020-10-30
Volume
73
Issue
9
Pages
e2838-e2839
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
DOI
10.1093/cid/ciaa1594
PMC
PMC7665423
OpenAlex
W3095711772
Cited by
112
References
5
Citations by year
2026: 4 · 2025: 7 · 2024: 16 · 2023: 22 · 2022: 37 · 2021: 24 · 2020: 2
Type
journal article
Language
en
Open access
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Oncology › COVID-19 and healthcare impacts
Keywords
candidemia, COVID-19 pandemic, SARS-CoV-2, invasive fungal infections, candidemia incidence, risk factors, antifungal prophylaxis, antifungal therapy, hospitalized patients, SARS-CoV-2 serology, SARS-CoV-2 viral load
MeSH terms
COVID-19, SARS-CoV-2, Humans, Prospective Studies, Incidence, Candidemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review